Therapeutic activity of high-dose intratumoral IFN-β requires direct effect on the tumor vasculature

Journal of Immunology

Volumn 193, Issue 8, 2014, Pages 4254-4260

  Spaapen, Robbert M ^a   Leung, Michael Y K ^a   Fuertes, Mercedes B ^a   Kline, Justin P ^b   Zhang, Long ^a   Zheng, Yan ^a   Fu, Yang Xin ^a   Luo, Xixi ^a   Cohen, Kenneth S ^a   Gajewski, Thomas F ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON RECEPTOR; ANGIOPOIETIN RECEPTOR; BETA INTERFERON RECEPTOR; RECOMBINANT BETA INTERFERON; ALPHA BETA INTERFERON RECEPTOR; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BETA INTERFERON; CD274 PROTEIN, MOUSE; IFNAR1 PROTEIN, MOUSE; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, MOUSE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; ENDOTHELIUM CELL; EX VIVO STUDY; IN VIVO STUDY; MELANOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR VASCULARIZATION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DRUG EFFECTS; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; LYMPHOCYTE DEPLETION; MELANOMA, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; TUMOR CELL LINE; TUMOR MICROENVIRONMENT; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; CELL LINE, TUMOR; INTERFERON-BETA; KILLER CELLS, NATURAL; LYMPHOCYTE DEPLETION; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOVASCULARIZATION, PATHOLOGIC; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTOR, INTERFERON ALPHA-BETA; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 84907495019     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1401109     Document Type: Article

References (38)

1. Gutterman, J. U. 1994. Cytokine therapeutics: lessons from interferon alpha. Proc. Natl. Acad. Sci. USA 91: 1198-1205.
2. Kirkwood, J. M., M. H. Strawderman, M. S. Ernstoff, T. J. Smith, E. C. Borden, and R. H. Blum. 1996. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol. 14: 7-17.
3. Fuertes, M. B., A. K. Kacha, J. Kline, S. R.Woo, D. M. Kranz, K. M. Murphy, and T. F. Gajewski. 2011. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8alpha+ dendritic cells. J. Exp. Med. 208: 2005-2016.
4. Diamond, M. S., M. Kinder, H. Matsushita, M. Mashayekhi, G. P. Dunn, J. M. Archambault, H. Lee, C. D. Arthur, J. M. White, U. Kalinke, et al. 2011. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J. Exp. Med. 208: 1989-2003
5. Fuertes, M. B., S. R. Woo, B. Burnett, Y. X. Fu, and T. F. Gajewski. 2013. Type I interferon response and innate immune sensing of cancer. Trends Immunol. 34: 67-73.
6. Gajewski, T. F., H. Schreiber, and Y. X. Fu. 2013. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 14: 1014-1022.
7. Gajewski, T. F., S. R. Woo, Y. Zha, R. Spaapen, Y. Zheng, L. Corrales, and S. Spranger. 2013. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr. Opin. Immunol. 25: 268-276.
8. Spranger, S., R. M. Spaapen, Y. Zha, J. Williams, Y. Meng, T. T. Ha, and T. F. Gajewski. 2013. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci. Transl. Med. 5: 200ra116.
9. Yang, X., X. Zhang, M. L. Fu, R. R. Weichselbaum, T. F. Gajewski, Y. Guo, and Y. X. Fu. 2014. Targeting the tumor microenvironment with interferon-b bridges innate and adaptive immune responses. Cancer Cell 25: 37-48.
10. Qin, X. Q., N. Tao, A. Dergay, P. Moy, S. Fawell, A. Davis, J. M. Wilson, and J. Barsoum. 1998. Interferon-beta gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice. Proc. Natl. Acad. Sci. USA 95: 14411-14416.
11. Ryuke, Y., M. Mizuno, A. Natsume, O. Suzuki, M. Nobayashi, T. Kageshita, K. Matsumoto, T. Saida, and J. Yoshida. 2003. Growth inhibition of subcutaneous mouse melanoma and induction of natural killer cells by liposome-mediated interferon-beta gene therapy. Melanoma Res. 13: 349-356.
12. Kim, H. S., and M. S. Lee. 2007. STAT1 as a key modulator of cell death. Cell. Signal. 19: 454-465.
13. Qin, X. Q., C. Beckham, J. L. Brown, M. Lukashev, and J. Barsoum. 2001. Human and mouse IFN-beta gene therapy exhibits different anti-tumor mechanisms in mouse models. Mol. Ther. 4: 356-364.
14. Indraccolo, S. 2010. Interferon-alpha as angiogenesis inhibitor: learning from tumor models. Autoimmunity 43: 244-247.
15. Indraccolo, S., U. Pfeffer, S. Minuzzo, G. Esposito, V. Roni, S. Mandruzzato, N. Ferrari, L. Anfosso, R. Dell'Eva, D. M. Noonan, et al. 2007. Identification of genes selectively regulated by IFNs in endothelial cells. J. Immunol. 178: 1122-1135.
16. Oliveira, I. C., P. J. Sciavolino, T. H. Lee, and J. Vilcek. 1992. Downregulation of interleukin 8 gene expression in human fibroblasts: unique mechanism of transcriptional inhibition by interferon. Proc. Natl. Acad. Sci. USA 89: 9049-9053.
17. von Marschall, Z., A. Scholz, T. Cramer, G. Schäfer, M. Schirner, K. Oberg, B. Wiedenmann, M. Höcker, and S. Rosewicz. 2003. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J. Natl. Cancer Inst. 95: 437-448.
18. Jablonska, J., S. Leschner, K. Westphal, S. Lienenklaus, and S. Weiss. 2010. Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model. J. Clin. Invest. 120: 1151-1164.
19. Dong, Z., G. Greene, C. Pettaway, C. P. Dinney, I. Eue, W. Lu, C. D. Bucana, M. D. Balbay, D. Bielenberg, and I. J. Fidler. 1999. Suppression of angiogenesis, tumorigenicity, and metastasis by human prostate cancer cells engineered to produce interferon-beta. Cancer Res. 59: 872-879.
20. Izawa, J. I., P. Sweeney, P. Perrotte, D. Kedar, Z. Dong, J. W. Slaton, T. Karashima, K. Inoue, W. F. Benedict, and C. P. Dinney. 2002. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis. Clin. Cancer Res. 8: 1258-1270.
21. Rozera, C., D. Carlei, P. L. Lollini, C. De Giovanni, P. Musiani, E. Di Carlo, F. Belardelli, and M. Ferrantini. 1999. Interferon (IFN)-beta gene transfer into TS/A adenocarcinoma cells and comparison with IFN-alpha: differential effects on tumorigenicity and host response. Am. J. Pathol. 154: 1211-1222.
22. Kline, J., L. Zhang, L. Battaglia, K. S. Cohen, and T. F. Gajewski. 2012. Cellular and molecular requirements for rejection of B16 melanoma in the setting of regulatory T cell depletion and homeostatic proliferation. J. Immunol. 188: 2630-2642.
23. Spiotto, M. T., P. Yu, D. A. Rowley, M. I. Nishimura, S. C. Meredith, T. F. Gajewski, Y. X. Fu, and H. Schreiber. 2002. Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity 17: 737-747.
24. Spaapen, R., K. van den Oudenalder, R. Ivanov, A. Bloem, H. Lokhorst, and T. Mutis. 2007. Rebuilding human leukocyte antigen class II-restricted minor histocompatibility antigen specificity in recall antigen-specific T cells by adoptive T cell receptor transfer: implications for adoptive immunotherapy. Clin. Cancer Res. 13: 4009-4015.
25. Kline, J., I. E. Brown, Y. Y. Zha, C. Blank, J. Strickler, H. Wouters, L. Zhang, and T. F. Gajewski. 2008. Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma. Clin. Cancer Res. 14: 3156-3167.
26. Kisanuki, Y. Y., R. E. Hammer, J. Miyazaki, S. C. Williams, J. A. Richardson, and M. Yanagisawa. 2001. Tie2-Cre transgenic mice: a new model for endothelial cell-lineage analysis in vivo. Dev. Biol. 230: 230-242.
27. Bottomley, A., C. Coens, S. Suciu, M. Santinami, W. Kruit, A. Testori, J. Marsden, C. Punt, F. Salès, M. Gore, et al. 2009. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J. Clin. Oncol. 27: 2916-2923.
28. Eggermont, A. M., S. Suciu, A. Testori, M. Santinami, W. H. Kruit, J. Marsden, C. J. Punt, F. Salès, R. Dummer, C. Robert, et al. 2012. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J. Clin. Oncol. 30: 3810-3818.
29. Escudier, B., A. Pluzanska, P. Koralewski, A. Ravaud, S. Bracarda, C. Szczylik, C. Chevreau, M. Filipek, B. Melichar, E. Bajetta, et al.; AVOREN Trial investigators. 2007. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370: 2103-2111.
30. Escudier, B., J. Bellmunt, S. Négrier, E. Bajetta, B. Melichar, S. Bracarda, A. Ravaud, S. Golding, S. Jethwa, and V. Sneller. 2010. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J. Clin. Oncol. 28: 2144-2150.
31. Bracarda, S., C. Porta, C. Boni, A. Santoro, C. Mucciarini, A. Pazzola, E. Cortesi, D. Gasparro, R. Labianca, F. Di Costanzo, et al. 2013. Could interferon still play a role in metastatic renal cell carcinoma? A randomized study of two schedules of sorafenib plus interferon-alpha 2a (RAPSODY). Eur. Urol. 63: 254-261.
32. Melichar, B., S. Bracarda, V. Matveev, B. Alekseev, S. Ivanov, A. Zyryanov, R. Janciauskiene, E. Fernebro, P. Mulders, S. Osborne, et al.; BEVLiN Investigators. 2013. A multinational phase II trial of bevacizumab with low-dose interferon-α2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN. Ann. Oncol. 24: 2396-2402.
33. Rini, B. I., J. Bellmunt, J. Clancy, K. Wang, A. G. Niethammer, S. Hariharan, and B. Escudier. 2014. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J. Clin. Oncol. 32: 752-759.
34. Hwang, T. H., A. Moon, J. Burke, A. Ribas, J. Stephenson, C. J. Breitbach, M. Daneshmand, N. De Silva, K. Parato, J. S. Diallo, et al. 2011. A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma. Mol. Ther. 19: 1913-1922.
35. Brody, J.D.,W. Z.Ai,D.K.Czerwinski, J.A. Torchia,M. Levy,R.H.Advani,Y.H.Kim, R. T. Hoppe, S. J. Knox, L. K. Shin, et al. 2010. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J. Clin. Oncol. 28: 4324-4332.
36. Li, J., W. Song, D. K. Czerwinski, B. Varghese, S. Uematsu, S. Akira, A. M. Krieg, and R. Levy. 2007. Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J. Immunol. 179: 2493-2500.
37. Teijaro, J. R., C. Ng, A. M. Lee, B. M. Sullivan, K. C. Sheehan, M. Welch, R. D. Schreiber, J. C. de la Torre, and M. B. Oldstone. 2013. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 340: 207-211.
38. Wiesel, M., J. Crouse, G. Bedenikovic, A. Sutherland, N. Joller, and A. Oxenius. 2012. Type-I IFN drives the differentiation of short-lived effector CD8+ T cells in vivo. Eur. J. Immunol. 42: 320-329